文献速递白血病淋巴瘤

高危慢性淋巴细胞白血病一线治疗后来那度胺维持治疗(CLLM1):随机双盲3期研究最终结果

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
PubMed 文献 · Lancet Haematol · 2017-09-12

CLLM1研究纳入经化疗免疫治疗后未达微小残留病阴性的高危慢性淋巴细胞白血病患者,随机2:1接受来那度胺或安慰剂维持治疗。独立审查的无进展生存风险比为0.168(95%CI 0.074-0.379),安慰剂组中位无进展生存13.3个月,来那度胺组未达到。

要点

  • 来那度胺维持治疗降低高危CLL患者进展风险,HR 0.168(95%CI 0.074-0.379)。
  • 安慰剂组中位无进展生存13.3个月,来那度胺组未达到。
  • 来那度胺组皮肤疾病35例(63%) vs 安慰剂组8例(28%);血液学毒性28例(50%) vs 5例(17%)。

核心结论

  • 来那度胺是有效的维持治疗,可降低一线化疗免疫治疗后未达微小残留病阴性的CLL患者的相对进展风险。
  • 考虑到合格患者的不良预后,来那度胺的毒性似乎可接受。
  • 该试验独立证实了一种基于微小残留病的新算法对预测短无进展生存期的临床意义,未来临床试验可能纳入该算法以识别额外维持治疗的候选者。

研究设计与样本

  • 随机、双盲、3期研究(CLLM1;德国CLL研究组CLL Maintenance 1),纳入年龄>18岁、免疫表型确诊活动性疾病、一线化疗免疫治疗结束后2-5个月有缓解、且经4个或以上周期一线化疗免疫治疗后至少部分缓解并评估为早期进展高风险的患者。
  • 合格条件为微小残留病高水平,或中等水平合并IGHV基因未突变状态或TP53改变。
  • 患者按2:1随机分配接受来那度胺5 mg或安慰剂,随机化采用固定区组大小3,并按一线治疗后达到的微小残留病水平分层。
  • 维持治疗从每日5 mg开始,逐步递增至目标剂量15 mg;如可耐受,给药至疾病进展。
  • 主要终点为独立审查评估的无进展生存期;计划中的中期分析在意向治疗人群中进行,于计算的无进展生存事件达到20%后进行。

主要发现

  • 2012年7月5日至2016年3月15日筛查468例既往未治疗的CLL患者,379例(81%)不符合条件;计划入组200例,实际随机89例后因入组不佳提前终止招募。
  • 60例(67%)随机分配至来那度胺组,29例(33%)至安慰剂组;其中56例(63%)接受来那度胺,29例(33%)接受安慰剂;数据截止时中位治疗周期数为11.0(IQR 4.5-20.5)。
  • 中位观察时间17.9个月(IQR 9.1-28.1)后,独立审查评估的无进展生存风险比为0.168(95%CI 0.074-0.379)。
  • 安慰剂组中位无进展生存13.3个月(95%CI 9.9-19.7),来那度胺组未达到(95%CI 32.3-不可评估)。
  • 最常见不良事件:皮肤疾病来那度胺组35例(63%) vs 安慰剂组8例(28%);胃肠道疾病34例(61%) vs 8例(28%);感染30例(54%) vs 19例(66%);血液学毒性28例(50%) vs 5例(17%);一般性疾病28例(50%) vs 9例(31%)。

关键数值与推荐

  • 随机分组比例2:1(来那度胺:安慰剂),按一线治疗后微小残留病水平分层。
  • 来那度胺起始剂量5 mg每日,递增至目标剂量15 mg。
  • 主要终点无进展生存的独立审查HR 0.168(95%CI 0.074-0.379)。
  • 安慰剂组中位无进展生存13.3个月(95%CI 9.9-19.7),来那度胺组未达到(95%CI 32.3-不可评估)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 计划入组200例,实际随机89例后因入组不佳提前终止招募。
  • 中位观察时间17.9个月(IQR 9.1-28.1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combined use of genetic markers and detectable minimal residual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line chemoimmunotherapy. We aimed to assess lenalidomide maintenance therapy in these high-risk patients. METHODS: In this randomised, double-blind, phase 3 study (CLLM1; CLL Maintenance 1 of the German CLL Study Group), patients older than 18 years and diagnosed with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded to chemoimmunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a high risk for an early progression with at least a partial response after four or more cycles of first-line chemoimmunotherapy, were eligible if they had high minimal residual disease levels or intermediate levels combined with an unmutated IGHV gene status or TP53 alterations. Patients were randomly assigned (2:1) to receive either lenalidomide (5 mg) or placebo. Randomisation was done with a fixed block size of three, and was stratified according to the minimal residual disease level achieved after first-line therapy. Maintenance was started with 5 mg daily, and was escalated to the target dose of 15 mg. If tolerated, medication was administered until disease progression. The primary endpoint was progression-free survival according to an independent review. The pre-planned interim analysis done by intention to treat was done after 20% of the calculated progression-free survival events. This study is registered with ClinicalTrials.gov, number NCT01556776; treatment in the lenalidomide group is still ongoing. FINDINGS: Between July 5, 2012, and March 15, 2016, 468 previously untreated patients with chronic lymphocytic leukaemia were screened for the study; 379 (81%) were not eligible. Recruitment was closed prematurely due to poor accrual after 89 of 200 planned patients were randomly assigned: 60 (67%) enrolled patients were assigned to the lenalidomide group and 29 (33%) to the placebo group, of whom 56 (63%) received lenalidomide and 29 (33%) placebo, with a median of 11·0 (IQR 4·5-20·5) treatment cycles at data cutoff. After a median observation time of 17·9 months (IQR 9·1-28·1), the hazard ratio for progression-free survival assessed by an independent review was 0·168 (95% CI 0·074-0·379). Median progression-free survival was 13·3 months (95% CI 9·9-19·7) in the placebo group and not reached (95% CI 32·3-not evaluable) in the lenalidomide group. The most frequent adverse events were skin disorders (35 patients [63%] in the lenalidomide group vs eight patients [28%] in the placebo group), gastrointestinal disorders (34 [61%] vs eight [28%]), infections (30 [54%] vs 19 [66%]), haematological toxicity (28 [50%] vs five [17%]), and general disorders (28 [50%] vs nine [31%]). One fatal adverse event was reported in each of the treatment groups (one [2%] patient with fatal acute lymphocytic leukaemia in the lenalidomide group and one patient (3%) with fatal multifocal leukoencephalopathy in the placebo group). INTERPRETATION: Lenalidomide is an efficacious maintenance therapy reducing the relative risk of progression in first-line patients with chronic lymphocytic leukaemia who do not achieve minimal residual disease negative disease state following chemoimmunotherapy approaches. The toxicity seems to be acceptable considering the poor prognosis of the eligible patients. The trial independently confirms the clinical significance of a novel, minimal residual disease-based algorithm to predict short progression-free survival, which might be incorporated in future clinical trials to identify candidates for additional maintenance treatment. FUNDING: Celgene Corporation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Fink AM, Bahlo J, Robrecht S, et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017. PMID: 28916311. doi:10.1016/S2352-3026(17)30171-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。